Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target

CAR-T Digest - August 2020

03 Dec 2024: Gilead and Tubulis enter into exclusive option and license agreement to develop ADC candidate for select solid tumor target

Gilead Sciences and Tubulis have entered into an exclusive option and license agreement to develop an antibody-drug conjugate (ADC) targeting a solid tumor
Gilead will collaborate with Tubulis to leverage their proprietary Tubutecan and Alco5 platforms for ADC development
Tubulis will lead the early-stage research and development of the ADC candidate, which aims to address treatment challenges such as durability and off-target toxicity, using a Topoisomerase I inhibitor-based ADC with enhanced biophysical properties
Under the agreement, Tubulis will receive an upfront payment of $20 million, with additional potential payments up to $415 million, depending on milestones, and royalties on future product sales
If Gilead exercises its option to license the ADC program, it will take responsibility for further development and commercialization of any resulting products